Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

Samuel Dagogo-Jack, Richard E. Pratley, David Z.I. Cherney, Darren K. McGuire, Francesco Cosentino, Weichung J. Shih, Jie Liu, Robert Frederich, James P. Mancuso, Annaswamy Raji, Ira Gantz

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial'. Together they form a unique fingerprint.

Medicine & Life Sciences